DIRS.INFO The most relevant business & tech news

The FDA’s announcement on Oct. 2 declaring the shortage over meant that compounding pharmacists had to stop filling tirzepatide prescriptions. Simone Williams, 50, of Spartanburg, S.C was prescribed compounded tirzepatide in June 2023 after her Mounjaro savings card expired. Williams began taking compounded tirzepatide for weight loss last year after her Mounjaro savings card expired. Tirzepatide was on the FDA’s drug shortage list for nearly two years. ‘Peace of mind’Meanwhile, patients and compounding pharmacists are celebrating the FDA decision to allow tirzepatide compounding to continue.

Persons: Lilly’s, Mounjaro, Zepbound, semaglutide, Wegovy, drugmakers, tirzepatide, “, Simone Williams, S.C, Simone Williams Simone Williams, Williams, ” Williams, she’s, I’m, ”, Lilly, Michael Ganio, Ganio, Dr, Christopher McGowan, ” McGowan, ” Lilly, Jared Shapiro, ’ ” Shapiro, Elizabeth Kenly, ” Kenly, Kenly Organizations: Drug Administration, FDA, Association, American Society of Health, System, Outsourcing, Alliance, Pharmacy, APC Locations: Spartanburg, Spartanburg , South Carolina, U.S, Cary , North Carolina, Graham , North Carolina

☆ Stocks making the biggest moves midday: SoFi, Caterpillar, SiriusXM, Boeing and more
▼ + stars: | 2024-10-14 | by ( Pia Singh | In | ) www.cnbc.com time to read: +2 min

Check out the companies making headlines in midday trading: SoFi Technologies — Shares of the online personal finance company jumped 9.8% after SoFi announced a $2 billion agreement with Fortress Investment Group to grow its loan platform business. Crypto stocks — Stocks tied to cryptocurrencies surged as bitcoin gained more than 5% to top $66,000. Ibotta — Shares advanced 5.5% after Goldman Sachs upgraded Ibotta, a mobile platform that offers cash-back rewards, to buy from neutral. Flutter Entertainment — The online gambling stock rose 4% after Wells Fargo upgraded shares to overweight from equal weight, urging investors to buy the recent dip. Caterpillar — The industrial stock fell 1.7% after Morgan Stanley downgraded shares to underweight from equal weight.

Persons: SoFi, Warren Buffett's Berkshire Hathaway, Stocks, cryptocurrencies, bitcoin, AppLovin, Goldman Sachs, Goldman, Wells, Morgan Stanley, Eli Lilly's, —, Alex Harring, Brian Evans, Samantha Subin, Yun Li, Lisa Kailai Han, Pia Singh, Michelle Fox Organizations: Fortress Investment Group, Sirius XM Holdings, Berkshire, Sirius, Mara Holdings, Boeing, Walmart, of America, Caterpillar, U.S . Food, Drug Administration Locations: U.S

☆ Stocks making the biggest moves premarket: Flutter Entertainment, Boeing, SiriusXM, Caterpillar and more
▼ + stars: | 2024-10-14 | by ( Sean Conlon | ) www.cnbc.com time to read: +2 min

Crypto stocks – Stocks linked to cryptocurrencies rose as Bitcoin soared above $64,000 to start the week. Flutter Entertainment – The FanDuel parent company popped 4% after Wells Fargo upgraded shares to overweight , saying that investors should consider buying the stock following the recent sell-off. Boeing also postponed the delivery of its still-uncertified 777X wide-body plane and forecasted a wider-than-expected loss for the third quarter. Sirius XM Holdings – The audio entertainment company rose 3.5% after Warren Buffett's Berkshire Hathaway disclosed that it purchased more of the stock. Caterpillar – The industrial company slipped more than 2% after Morgan Stanley downgraded shares to underweight from equal weight.

Persons: MicroStrategy, Mara, Mara Holdings —, Coinbase, Wells, Warren Buffett's Berkshire Hathaway, Morgan Stanley, Goldman Sachs, AppLovin, Eli Lilly's, —, Alex Harring, Samantha Subin, Jesse Pound, Sarah Min, Hakyung Kim, Pia Singh Organizations: Mara Holdings, Boeing –, Boeing, Sirius XM Holdings, Berkshire, Sirius, Caterpillar, Walmart, Food and Drug Administration

☆ U.S. FDA to reconsider decision barring compounded versions of Lilly weight loss drug
▼ + stars: | 2024-10-12 | by ( ) www.cnbc.com time to read: +1 min

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs. The compounding versions of the drugs are cheaper for patients than the brand-name versions. The Sept. 30 decision by the FDA endangered the ability of compounders to sell versions of Lilly's weight loss drug Zepbound and diabetes drug Mounjaro. The FDA decision removed their active ingredient, tirzepatide, from its list of drugs experiencing shortages. Insurers generally cover drugs like tirzepatide for diabetes, but many do not cover them for weight loss.

Persons: Eli Lilly's, Mark Pittman Organizations: . Food, Drug Administration, Outsourcing, Association, District, FDA Locations: U.S, Fort Worth , Texas

☆ Ozempic-fueled slimming is blowing up the wedding dress industry
▼ + stars: | 2024-10-11 | by ( Allison Morrow | ) edition.cnn.com time to read: +6 min

New York CNN —Price distortions and dysfunction are nothing new in the $73 billion wedding industry. For better or worse, many brides are using the drugs ahead of their big day, lured in by the promise of rapid weight loss. The right fitThe ideal time to buy a wedding dress is eight to 10 months before the event, according to wedding planning site the Knot, and some planners recommend buying a full year in advance in case of shipping delays. “Usually, the dress was ordered somewhere in the middle of those 50 pounds.”It’s hard to overstate how such drastic weight loss can complicate a wedding dress’ fit. “Weight loss has always been a top of priority.

Persons: CNN Business ’, Tami Luhby, Susan Ruddie, Dresser, Spring, That’s, they’re, ”, Myrna Lundberg, “, Lundberg, ” Lundberg, “ It’s, — it’s, you’re Organizations: CNN Business, New York CNN, FDA, Drug Administration, Bureau of Labor Statistics, CNN Locations: New York, China, Suez, United States

☆ Friday's analyst calls: Goldman raises Nvidia target, JPMorgan upgrades Ferrari
▼ + stars: | 2024-10-11 | by ( Hakyung Kim | In Hakyungkim | ) www.cnbc.com time to read: +4 min

(This is CNBC Pro's live coverage of Thursday's analyst calls and Wall Street chatter. Ferrari's scarcity-driven growth strategy has contributed to price growth of as much as 30% for new vehicles compared to prior vehicles, per Brinkman. — Hakyung Kim 6:25 a.m. Morgan Stanley raises Eli Lilly estimates Morgan Stanley notched its price target for Eli Lilly shares higher on increased weight-loss drug estimates. — Hakyung Kim 6:00: am Goldman Sachs raises Nvidia price target Goldman Sachs believes strong demand for artificial intelligence compute should help drive Nvidia shares higher. Analyst Toshiya Hari increased his price target on Nvidia shares to $150 from $135, implying 11.3% upside potential from Thursday's close.

Persons: Goldman, Morgan Stanley, Elli Lilly, Ryan Brinkman, Brinkman, Ferrari, — Hakyung Kim, Eli Lilly, Terence Flynn, Zepbound, Eli Lilly's, Mounjaro, Flynn, Mercado, Gonzalo Lopez, Lopez, Mercado Credito, Goldman Sachs, Toshiya Hari, Hari, Hakyung Kim Organizations: CNBC, Nvidia, JPMorgan, Ferrari, Mercado Libre, company's Data Locations: Thursday's, Latin America, U.S, America, verticals, Hari

☆ Novo and Eli contender Zealand Pharma heralds its obesity drug alternative: It's our 'crown jewel'
▼ + stars: | 2024-10-11 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +4 min

Jaap Arriens | NurPhotoDanish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market dominated by heavyweights Novo Nordisk and Eli Lilly . Last month, Zealand Pharma announced positive top-line results from a phase 1b trial of its weight-loss drug, a GLP-1/GLP-2 receptor dual agonist called Dapiglutide. Stock Chart Icon Stock chart icon Zealand Pharma. Novo Nordisk is also experimenting with its own version of the treatment, combining the GLP-1 component Semaglutide with amylin analog Cagrilintide in a candidate called CagriSema. Syringes from weight loss drugs "Wegovy," "Ozempic" and "Mounjaro."

Persons: Jaap Arriens, Eli Lilly, Adam Steensberg, Steensberg Organizations: Zealand Pharma, Novo Nordisk, CNBC, pharma, Nordisk, Union, Getty Locations: U.S

All four drugs are in a class of wildly popular weight loss drugs known as GLP-1s. In the United Kingdom, authorities last year seized hundreds of counterfeit Ozempic pens — insulin pens that had been relabeled as Ozempic. Counterfeit weight loss drugs have serious health risks, according to the pharmaceutical companies and federal officials. Counterfeiters are already trying to cash in on a weight loss drug that the company hasn't even put on the market yet: retatrutide. But it's also one of the epicenters of the lucrative counterfeit drug trade, according to U.S. authorities who track counterfeit drugs.

Persons: It's, —, Eli Lilly's Mounjaro, they've, Laver, Andy Morling, CNBC Morling, Eli Lilly, Daniel Skovronsky, Eli Lilly's, we'll, Skovronksy, John F, Sal Ingrassia, Ingrassia, Customs isn't, we've, Yoav Keren, GLP, TikTok, Keren, BrandShield, it's, Nicole Johnson, CNBC Johnson, Johnson, Mike Doustdar, Doustdar, Direnc Bada Organizations: CNBC, U.S, Laver Beauty, DHL, Novo Nordisk, Laver, Medicines, Healthcare Products Regulatory Agency, Lilly Research Labs, Kennedy International, JFK International Mail Facility, U.S . Customs, Border Protection, JFK, CBP, Protection, CNBC CNBC, FDA, Customs, Meta, Facebook, World Health Organization, U.S ., Intellectual, Coordination Center, National, Turkish National Police, Novo Nordisk's, CNBC Counterfeiters, CNBC FDA Locations: BOULDER, COLO, Boulder, Ozempic, Shijiazhuang, China, Beijing, Englewood Cliffs , New Jersey, United Kingdom, London, New York City, U.S, Turkey, Europe, South America, United States, India, Mexico, Istanbul, Zurich

☆ Bernstein upgrades Campbell as people taking GLP-1 drugs eating more soup
▼ + stars: | 2024-10-07 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

Campbell Soup could be poised to benefit from an uptick in GLP-1 drug usage, according to Bernstein. Among the 20 analysts covering Campbell, only five have a strong buy or buy rating, while 12 have a hold rating. In addition, the analyst anticipates that reduced chocolate consumption from GLP-1 intake may hinder U.S. chocolate volumes by 2% to 3%. "Unfortunately, chocolate category volumes remain stubbornly negative and Hershey's chocolate volumes also remain weak despite lapping easier and easier comparables in recent months," Howard continued. Meanwhile, only four have a strong buy or buy rating, and its average target of $202.14 implies a gain of about 5% ahead.

Persons: Campbell, Bernstein, Eli Lilly's Mounjaro, Alexia Howard, Milano, Howard, they've Organizations: Nordisk's Ozempic, Hershey Locations: GLP

☆ 10 things to watch in the market Thursday, including great news from Nvidia's CEO
▼ + stars: | 2024-10-03 | by ( Jeff Marks | ) www.cnbc.com time to read: +7 min

My top 10 things to watch Thursday, Oct. 3 Today's newsletter was written by the Investing Club's director of portfolio analysis, Jeff Marks. But the analysts said they would be buyers of the Club stock on weakness in 2025. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. My top 10 things to watch Thursday, Oct. 3Today's newsletter was written by the Investing Club's director of portfolio analysis, Jeff Marks. But the analysts said they would be buyers of the Club stock on weakness in 2025.

Persons: Jeff Marks, Stocks, Dow, Beer, Jensen Huang, Blackwell, Eli Lilly, Morgan Stanley, Oppenheimer, Levi Strauss, Levi, Jim Cramer's, Jim Cramer, Jim Organizations: Nasdaq, Constellation Brands, Modelo, Corona, Constellation, Nvidia, CNBC, Club, Bank of America, Devices, Amazon, Deutsche Bank, Costco, Dockers, Barclays, PepsiCo, Jim Cramer's Charitable Locations: Northern New Jersey, Europe, Americas

☆ How the port strike could actually boost Costco sales
▼ + stars: | 2024-10-03 | by ( Paulina Likos | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Club stock Nvidia jumped more than 3% — bucking the pressure on Big Tech. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Jensen Huang, Eli Lilly, Lilly, Oppenheimer, Jim Cramer's, Jim Organizations: CNBC, Wall, Nvidia, Big Tech, Blackwell, Broadcom, Devices, Food and Drug Administration, Costco, AMD Locations: New Jersey

☆ Stocks making the biggest moves midday: Hims & Hers Health, Joby Aviation, Levi Strauss and more
▼ + stars: | 2024-10-03 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

EVgo — Shares soared 55% after the electric vehicle charger company received a $1.05 billion conditional loan from the Department of Energy. Hims & Her Health had previously developed compound versions of the drugs to take advantage of the shortage. Joby Aviation – Shares dropped more than 7%, paring back gains made in the previous session. Palantir recently announced that it's partnering with Edgescale AI to deliver Live Edge, a platform that will utilize artificial intelligence for manufacturing, utilities and other areas. Investors see both Vistra and Constellation as becoming key supporters of data center growth for developing tech companies' artificial intelligence technologies.

Persons: Bill Peterson, Eli Lilly, paring, Joby, Levi Strauss, Levi, Jensen Huang, CNBC's, Blackwell, Henning Cosman, Palantir, Sundar Pichai, Yun Li, Lisa Kailai Han, Hakyung Kim Organizations: Department of Energy, JPMorgan, U.S . Food, Drug Administration, Toyota, Dockers, Wolfspeed, Mizuho, Nvidia, Barclays, Constellation Energy, Nikkei, Investors Locations: U.S, China

☆ Here are JPMorgan's top stock picks heading into October
▼ + stars: | 2024-10-02 | by ( Sean Conlon | ) www.cnbc.com time to read: +4 min

For October, the additions include Best Buy and Carmax , while Wayfair , CarGurus and First Citizens BancShares are among those removed. The bank cited positive existing home sales, and an expansion in AI adoption, believing Best Buy will see continued growth in average selling prices . Analyst Christopher Horvers says Best Buy will increase its profitability over time, noting an uptick in operating margins to 5% from last year's 4.1%. He has an overweight rating on the stock, and his price target of $111 implies more than 9% upside from Tuesday's close. The bank's price target for Schwab implied about 22% upside and for Ulta Beauty about 18% potential appreciation, based on Tuesday's close.

Persons: JPMorgan's, Christopher Horvers, BBY, Eli Lilly, Lilly, Charles Schwab, Schwab Organizations: JPMorgan, Nasdaq, Dow Jones, Wall, AT, TPG Locations: Israel, Richland , Minnesota, Dallas, DirectTV, Lilly, Ireland

☆ Eli Lilly to build $4.5 billion research and manufacturing center to propel drug pipeline
▼ + stars: | 2024-10-02 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com time to read: +2 min

Eli Lilly will spend $4.5 billion to build a center aimed at finding better ways to manufacture its medicines. The facility, called the Lilly Medicine Foundry, will house development of new manufacturing methods with an eye toward efficiency. It's a strategy that's already paying off with Lilly's obesity and weight loss drugs Mounjaro and Zepbound, and Lilly wants it to propel the rest of its pipeline. Lilly says the facility will be the first of its kind to combine research and production in a single location. It will be near a $9 billion manufacturing complex Lilly is building in Lebanon, Indiana, to produce pharmaceutical ingredients like tirzepatide, the active ingredient in Mounjaro and Zepbound.

Persons: Eli Lilly, Mounjaro, Lilly, David Ricks, –, Dan Skovronsky Organizations: Lilly, Foundry, Indianapolis, Novo Nordisk's Ozempic Locations: Indianapolis, Lebanon , Indiana, tirzepatide

☆ Port strike fallout: Blockbuster weight-loss drug supply from Wegovy to Ozempic, Mounjaro, Zepbound caught up in East Coast trade shutdown
▼ + stars: | 2024-10-01 | by ( Lori Ann Larocco | ) www.cnbc.com time to read: +3 min

In this article LLYNOVO.B-DK Follow your favorite stocks CREATE FREE ACCOUNTAn Eli Lilly & Co. Zepbound injection pen, March 28, 2024. Bills of lading, the digital receipts of freight containers, show that the delivery mechanisms for insulin and weight-loss drugs rely on East Coast ports for incoming trade. "Novo Nordisk and Eli Lilly are both heavily reliant on the Port of Norfolk," said William George, director of Research at ImportGenius, which tracks the customs data. Vials on the Wegovy line at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Friday, March 8, 2024. Bloomberg | Bloomberg | Getty ImagesAn Eli Lilly spokesperson said it does not discuss the details of its external supplier relationships.

Persons: Eli Lilly, Eli Lilly — Ozempic, William George, George, Dennis Monts Organizations: Bloomberg, Getty, Novo Nordisk, ILA, Nordisk, Research, U.S . Senate, CNBC, Nuco Logistics Locations: New England, Texas, U.S, lading, East Coast, Port of Norfolk, ImportGenius, Norfolk, airfreight, Hillerod, Denmark, Monts

☆ The one sector of the stock market that is cheap with upside today
▼ + stars: | 2024-09-29 | by ( Karen Firestone | ) www.cnbc.com time to read: +5 min

The table and chart below illustrate some characteristics of the biopharma stocks. The average price/earnings multiple for the group, using 2025 estimates, is 12.7 times versus 20.6 times for the S & P 500. A major knock on the biopharma group is the limited productivity from their extremely expensive research efforts, other than obesity drugs, over the past twenty-five years. The technology using AI might not be ready yet, particularly related to the complex biology of the human body. Complex programs exist already, such as AlphaFold, which predicts the structure of three-dimensional compounds using data on protein sequences.

Persons: Bristol Myers, Amgen, Eli Lilly, Lilly, Johnson Organizations: CNBC, Merck, Pfizer, Novo Nordisk, JPMorgan Locations: Bristol

☆ Insider Today: Austin's genius housing fix
▼ + stars: | 2024-09-28 | by ( Joi-Marie Mckenzie | ) www.businessinsider.com time to read: +7 min

This week's dispatchThe high cost of weight-loss drugsiStock; Rebecca Zisser/BIWhy are two popular weight-loss drugs — Wegovy and diabetes medication Ozempic — so expensive in the US? Patients also bargain-hunt for cheaper weight-loss drugs online, or try to use manufacturer-issued coupons. See the full listiStock; Rebecca Zisser/BIDeals we loveCalling all Madewell shoppers: The bi-annual Madewell Insiders sale is here with 25% off almost everything full-price and an additional 40% off sale. The bi-annual Madewell Insiders sale is here with 25% off almost everything full-price and an additional 40% off sale. The Insider Today team: Dan DeFrancesco, deputy editor and anchor, in New York City.

Persons: —, you've, Shailene Woodley, George Clooney, Rebecca Zisser, Ozempic, Lars Fruergaard Jorgensen, Sen, Bernie Sanders, it's, Gabby Landsverk, Ro, Henry Meds, Eli Lilly, Stefania Pelfini, Jenny Chang, Rodriguez, BI Marie, Mangin, Yellowstone Joey Hadden, Jackson, Wyoming's, Natalie Ammari, Zers, Austin, Tyler Le, Dan DeFrancesco, Jordan Parker Erb, Lisa Ryan, Amanda Yen, Grace Lett Organizations: Business, Service, Novo Nordisk, Federal Trade Commission, FDA, copycats, BI, Yellowstone, Austin, Lone Star, Disney, Pixar, British, Netflix, Insiders Locations: Washington ,, Germany, New York City, New York, Chicago

☆ A doctor shares how his patients are trying to afford weight-loss drugs — and what happens if they can't
▼ + stars: | 2024-09-27 | by ( ) www.businessinsider.com time to read: +4 min

The high price of weight-loss drugs is frustrating for patients who can't access them, a doctor said. Patients struggle to afford these drugs, leading to cycling, rationing, or using risky alternatives. AdvertisementPharmaceutical companies are facing a new wave of criticism for the high price of groundbreaking weight-loss drugs. The latest generation of these class of drugs, medications like Ozempic, Wegovy, Mounjaro, and Zepbound, are once-weekly injections. The competitive pressure will also help drive prices lower as companies aim to attract consumers back to their brand with cheaper options for weight-loss drugs.

Persons: —, Dr, Christopher McGowan, McGowan, that's, they've, Ted Kyle, Kyle Organizations: Service, Pharmaceutical, FDA

☆ Weight-loss drugs are life-changing — and expensive. Here's one woman's solution.
▼ + stars: | 2024-09-26 | by ( ) www.businessinsider.com time to read: +7 min

A woman who had life-changing results on a popular weight loss drug struggled to afford it for years. AdvertisementTara Rothenhoefer, a 49-year-old Florida resident, says her life changed when she joined a clinical trial for a promising new weight-loss medication. While regulated, these compounded drugs aren't FDA-approved, raising concerns from doctors about variations in quality. The grey market of weight-loss drugs is vast and complicated. In August, Eli Lilly halved the price of its weight-loss drug Zepbound through single-dose vials — a bid to lure customers back to brand-name drugs, analysts said.

Persons: —, Tara Rothenhoefer, Rothenhoefer, Eli Lilly, She's Organizations: Service, Novo Nordisk's, Research, FDA, Pharmaceutical Locations: Florida

☆ ‘Greed, greed, greed’: Sanders demands Ozempic maker lower prices
▼ + stars: | 2024-09-24 | by ( Meg Tirrell | Tami Luhby | ) edition.cnn.com time to read: +7 min

“We are very committed to making sure that Americans have access at an affordable price point for our medicines,” Jorgensen replied. Similarly, Wegovy’s list price is $1,349 in the US, but it costs $186 in Denmark, $140 in Germany and $92 in the United Kingdom, he said. Tuesday’s hearing boiled down to a familiar argument over who is responsible for the US’s higher prices: drug companies that set starting – or “list” – prices or pharmacy benefit managers, the middlemen that negotiate discounts on those list prices in exchange for favorable insurance coverage and access. Jorgensen said Novo Nordisk pays back about 75% of its medicine sales in rebates, discounts and fees, so the net price it receives is far lower than the list price. “The broad totality is that less patients have access to our medicines when we lowered the price,” Jorgensen told Sen. Maggie Hassan, D-New Hampshire, after she pressed him to reduce list prices.

Persons: Sen, Bernie Sanders, ” Sanders, Lars Fruergaard Jorgensen, ” Jorgensen, “, Sanders, Jorgensen, it’s, Maggie Hassan, drugmakers, ”, PBMs, scot, ” Sen, Tim Kaine, Roger Marshall, Eli Lilly, Dr, Sanjay Gupta, Tammy Baldwin Organizations: CNN, Nordisk’s, US, Health, Education, Labor, Pensions, Yale, Novo Nordisk’s Ozempic, Novo Nordisk, Pharmaceutical Care Management Association, Nordisk, Novo Nordisk’s, Federal Trade Commission, CVS, Cigna’s, Republican, Wegovy’s, CNN Health, Medicare, Services Locations: United States, Danish, America, Canada, Denmark, Germany, United Kingdom, New Hampshire, Big, Virginia, Kansas, Novo, Wisconsin

☆ Feel like GLP-1 weight loss drugs affect your mood? Experts weigh in
▼ + stars: | 2024-09-19 | by ( Madeline Holcombe | ) edition.cnn.com time to read: +9 min

Although originally prescribed to treat type 2 diabetes (Ozempic and Mounjaro), semaglutide and tirzepatide are becoming more and more popular for weight loss. If you are noticing an effect on your mood while using a GLP-1 medication, here’s what might be at play. Antidepressant effectsFor some, using a GLP-1 medication might relieve some anxiety or depression symptoms, Arillotta said. Blood sugarIf you feel like your mood takes a drop while you’re on GLP-1 medications, what and how much you’re eating or drinking might be to blame. “Extremes in blood sugar can impact mood,” said Tara Schmidt, lead dietitian at the Mayo Clinic Diet, an online weight loss program.

Persons: ideation, Thomas Wadden, Davide Arillotta, Arillotta, “, Peter Ueda, Amira Guirguis, ”, Tara Schmidt, ” Schmidt, Guirguis, Giuseppe Floresta, Fabrizio Schifano, ” Guirguis, aren’t, you’ve, Schmidt, “ I’m, Ueda Organizations: Lifeline, CNN, US Food and Drug Administration, Perelman School of Medicine, University of Pennsylvania, FDA, neurosciences, University of Florence, Karolinska Institutet, Diabetes, Swansea University, Mayo Clinic Diet, University of Catania, University of Hertfordshire, American Psychological Association, “ Locations: Italy, Stockholm, Sweden, GLP, Wales, United Kingdom

☆ I tried Nestlé's new weight-loss meals, and felt full for hours — but nutritionists have mixed reviews
▼ + stars: | 2024-09-18 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +9 min

This story is available exclusively to Business Insider subscribers. Vital PursuitThe meals cost less than $5 and are available at retailers including Target and Walmart, starting Wednesday, according to the company. These small meals, branded as protein-rich, are designed to help GLP-1 users lose more fat, and less muscle. "We want to be a brand for those 82% of Americans who are managing their weight," Stoehr told Business Insider, referencing a Morgan Stanley report. "These meals seem like a decent option... but not a great one," Malloy wrote in an email to Business Insider.

Persons: —, Nestlé, Kristen Stoehr, Stoehr, Morgan Stanley, We're, Alix Turoff, Mike Molloy, Hilary Brueck, I've, I'd, Turoff, Malloy, It's, that's, I'm, Nestlé's, Marlene Schmidt, Morgan Stanley's Organizations: Service, Business, Target, Walmart Locations: Nestlé, New York

WASHINGTON — Sen. Bernie Sanders, I-Vt., renewed his criticism of drugmaker Novo Nordisk on Tuesday, claiming that the CEOs of major generic pharmaceutical companies have told him that they can produce and sell its blockbuster diabetes drug Ozempic for less than $100 a month. During Tuesday's roundtable, Sanders said his recent conversations with generic drugmakers revealed that Novo Nordisk's pricing is "nothing less than excess corporate greed." “They have studied the math, and they tell me that they can sell a generic version of Ozempic, the exact same drug that Novo Nordisk is manufacturing, to Americans for less than $100 a month," Sanders said. Sanders’ office declined to say which generic drug companies told him that they could sell Ozempic at a fraction of what Novo Nordisk charges. Novo Nordisk did not immediately respond to a request for comment.

Persons: WASHINGTON — Sen, Bernie Sanders, Sanders, Lars Fruergaard Jorgensen's, Jorgensen, Wegovy, Dale Folwell, Eli Lilly's Organizations: drugmaker Novo Nordisk, Capitol, Novo Nordisk, Health, Education, Labor, Pensions, Wegovy, Nordisk, Yale Locations: U.S, Novo, Denmark, Germany, United Kingdom, North Carolina

☆ GLP-1 pills are coming, and they could revolutionize weight-loss treatment
▼ + stars: | 2024-09-17 | by ( Meg Tirrell | ) edition.cnn.com time to read: +7 min

CNN —Jared Holz thought about taking one of the new GLP-1 drugs for weight loss for months before he actually filled the prescription. At least a dozen similar experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, with the most advanced now in the third and final stage of testing. Dushay cited hopes that pill versions of GLP-1 drugs could ease shortages, come at lower cost and enhance convenience. The oral GLP-1 raceRight on the heels of oral semaglutide is a group of drugs led by Eli Lilly’s orforglipron, an oral medication that also targets GLP-1, which is a hormone implicated in insulin regulation, appetite and digestion. Drugmakers including Pfizer and Roche, as well as smaller companies like Structure Therapeutics, Terns Pharmaceuticals and Viking Therapeutics, also have oral weight-loss drugs in earlier stages of development, BMO research shows.

Persons: Jared Holz, ” Holz, ”, Jody Dushay, Dushay, ” Dushay, it’s, Rybelsus, Jorge Moreno, “, ” Moreno, Eli Lilly’s orforglipron, Lilly, Evan Seigerman, amycretin, who’ve, Dr, Sanjay Gupta, Holz, he’s, he’d Organizations: CNN, Harvard Medical School, Beth Israel Deaconess Medical, Novo Nordisk, US Food and Drug Administration, Yale School of Medicine, BMO Capital Markets, Pfizer, Roche, Therapeutics, Terns Pharmaceuticals, Viking Therapeutics, BMO, Nordisk, European Association for, Diabetes, Inversago Pharma, CNN Health Locations: Danish, Novo

☆ UBS says get defensive as global growth disappoints. Gives stocks to buy
▼ + stars: | 2024-09-17 | by ( Sean Conlon | ) www.cnbc.com time to read: +2 min

As global growth continues to slow, investors should get overweight on defensive names, according to UBS. August marked yet another month of declining global growth, as the Global Manufacturing Purchasing Managers' Index (PMI) reported 49.5 for the month , down from 49.7 in July, according to S & P Global Market Intelligence. Wall Street has taken a bullish stance, as 12 of the 18 analysts covering the stock have issued strong buy or buy ratings, according to LSEG. Constellation Energy has also been on a monster run this year, with shares surging 70%. About 82% of the analysts covering the stock rate it a buy or strong buy, according to LSEG.

Persons: Dow Jones, Eli Lilly, it's Organizations: UBS, Global Manufacturing, P Global Market Intelligence, Institute for Supply Management, Federal Reserve, Constellation Energy, Constellation Locations: Ireland

Search resuls for: "Mounjaro"

25 mentions found